Biotechnology

BrYet US, Inc. Files IND Application for ML-016, Lead Oncology Therapeutic for Advanced Solid Tumors with Lung and/or Liver Metastases

March 4, 2026 12:00 PM

BrYet US, Inc. ("BrYet") - a biotechnology innovator focused on developing curative therapies for advanced cancers - announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead drug, ML-016. Upon approval, the IND will support the expansion of BrYet's ML-016 clinical program with additional trials in the United States. "Submitting our first IND application is a...

Read more

Ablexis Reports 33 AlivaMab(R) Mouse-Derived Human Antibodies Now in Clinical Development, Further Validating AlivaMab Mouse Transgenic Platform

March 4, 2026 8:00 AM

Ablexis, LLC, a biopharmaceutical company advancing human antibody drug discovery through its AlivaMab Mouse platform, today announced that licensees have advanced at least 33 AlivaMab Mouse-derived antibody drug candidates into clinical development. Notably, at least two of these drug candidates have progressed into pivotal phase 3 clinical trials, marking a significant step toward potential regulatory approval and underscoring the growing...

Read more

Faron Pharmaceuticals Ltd's Annual Report 2025 Published

March 4, 2026 2:35 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today published the Annual Report for 2025. The Annual Report contains the Report of the Board of Directors, the Financial Statements for 2025 and the Remuneration Report. The English version of Annual Report is available as a PDF file attached to this release and on the company's website at...

Read more

Faron's Financial Statements Release 1 January to 31 December 2025

March 4, 2026 2:30 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Continued steady progress with bexmarilimab and solidifying position as a leading macrophage based immunotherapy under development Figures in parentheses refer to the corresponding period of previous year, unless otherwise indicated. The figures in this financial statements release are audited unless otherwise indicated. January-December 2025 highlights In 2025 Faron presented as an oral presentation...

Read more

BIO ESSENCE CORP (OTCQB:BIOE) Announces Approval for Upgrade to the OTCQB Market, Effective February 26, 2026

March 3, 2026 8:00 AM

BIO ESSENCE CORP. (the "Company" or "BIOE") (OTCQB:BIOE), a company dedicated to promoting wellness and vitality through a lifestyle supported by holistic products and practices and pursuing growth strategies that include AI-enabled platform initiatives, today announced that it has been approved to upgrade to the OTCQB® Venture Market by OTC Markets Group Inc. The Company's common stock is expected to begin trading on the OTCQB on February 26,...

Read more

MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation

March 3, 2026 2:45 AM

MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics, or the Company), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases, today provided a post-listing corporate update and published its March 2026 investor presentation. Alexandre Capet, Chief Executive Officer of MindMaze Therapeutics, stated, "Building on solid foundations, we are executing our roadmap to expand access to...

Read more

Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers

March 2, 2026 11:30 AM

Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX), today announced the launch of two updated educational websites focused on MCT8 deficiency for audiences across North America. The new websites-mct8deficiency.com for healthcare professionals and lifewithmct8deficiency.com for caregivers-replace the Company's previous single disease awareness website and are designed to deliver clearer, more comprehensive, and...

Read more

Prolocor(R) Research Named a "Top 10 Article of 2025" by the Journal of Invasive Cardiology

March 2, 2026 9:00 AM

Prolocor, Inc., a healthcare company developing the innovative diagnostic Prolocor pFCG™ test to identify patients at risk of thrombotic events, today announced that its recent publication, entitled "Prognostic Implications Over Time of Platelet FcγRIIa Expression in Patients with Myocardial Infarction," has been selected by the Journal of Invasive Cardiology (JIC) as one of the Editors' Top 10 Articles of 2025. The recognized research...

Read more

Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting

March 2, 2026 5:20 AM

Faron Pharmaceuticals Ltd (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the extraordinary general meeting (the "EGM") of the Company took place today, 2 March 2026 in Turku, Finland. The EGM approved the proposal of the Board of Directors ("Board") as set out in the notice to the EGM published on 9 February 2026. Decisions of the EGM Authorising the Board...

Read more

Alligator Bioscience Comments on Henlius Dosing First Patient in Phase 2/3 Breast Cancer Study of HLX22

March 2, 2026 3:05 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that the first patient has been dosed in a Phase 2/3 clinical trial of HLX22 in combination with HLX87 (an antibody-drug conjugate targeting HER2) as a first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer. The trial (NCT07294508) is conducted in Mainland China. HLX22 is an innovative anti-HER2...

Read more

Faron and City of Hope in Process of Developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS

March 2, 2026 2:15 AM

Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer, today announces that investigators at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, are in the process of developing a Phase II investigator-initiated clinical trial (IIT) in collaboration with Faron to evaluate bexmarilimab in...

Read more

Exercise Price Determined for the Exercise of Warrants Series TO 14 in Alligator Bioscience AB

February 27, 2026 12:45 PM

Alligator Bioscience (STO:ATORX) ("Alligator Bioscience" or the "Company") hereby announces that the exercise price for warrants series TO 14 (the "warrants") has been determined to SEK 0.20. The exercise period for the warrants commences on 5 March 2026 and runs up to and including 19 March 2026. The last day of trading in the warrants is 17 March 2026. Alligator Bioscience carried out a rights issue of units during October - December 2025 (the...

Read more

Year-End Report 2025

February 27, 2026 2:20 AM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today published the year-end report for 2025. "The fourth quarter marked an important period of execution and strategic progress for Vicore as we advanced buloxibutid as a potentially disease-modifying therapy for IPF. Building on the steady operational momentum throughout the year, we expanded...

Read more

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

February 26, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the filing of utility patent applications covering the architectural framework of its Agentic Harmonization Assistant ("AHA"), an internally developed AI-based data harmonization system. IGC is developing AHA to support the standardization of heterogeneous Alzheimer's disease...

Read more

Vicore Pharma to Present at Upcoming Investor Conferences

February 26, 2026 2:20 AM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Location: Boston, USA Format: Presentation and 1×1 meetings Presentation Date and Time: Wednesday, March 4 at 1:50 PM EST Webcast: Link Participants: Ahmed...

Read more

BioInvent International AB: Year-End Report January 1 - December 31, 2025

February 26, 2026 2:15 AM

BioInvent International (STO:BINV) - "During 2025 we sharpened our clinical focus and resource allocation to accelerate our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), while pausing earlier programs to maximize the probability of success and near-term value creation."- Martin Welschof, CEO BioInvent. EVENTS IN THE FOURTH QUARTER (R) Promising early Phase 2a monotherapy data for the company's lead anti-TNFR2 antibody...

Read more

Invitation to Presentation of BioInvent's Year-End Report 2025

February 26, 2026 1:50 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report 2025 on February 26 at 2:00 pm CET. The report will be published at 8:00 am CET today. BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English. When: Thursday February 26, 2026, at 2:00 pm CET The webcast can be reached at...

Read more

ONI Launches LNP PREP on Aplo Flow, Delivering Sample-to-Answer Automation for LNP Characterization

February 25, 2026 7:00 AM

Oxford Nanoimaging (ONI), a global leader in integrated super-resolution microscopy systems, today launches LNP PREP workflow on Aplo Flow, delivering a fully automated, sample-to-answer workflow for quantitative LNP characterization at single-particle resolution. Lipid nanoparticles (LNPs) are a foundational delivery technology for mRNA vaccines, gene therapies, and other advanced therapeutic modalities driving the next generation of drug...

Read more

FluoGuide A/S Publishes Annual Report For The Fiscal Year 2025

February 25, 2026 1:30 AM

FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) hereby publishes its annual report for the fiscal year 2025. The annual report, including the auditor's report is attached as a PDF and is also available on FluoGuide's website www.fluoguide.com under ‘Financial reports'. Following a year of significant clinical and regulatory progress in 2025, FluoGuide has reached a key inflection point in 2026. With the IND now cleared by FDA, we have...

Read more

FluoGuide A/S Publishes Interim Report For Q4 2025

February 25, 2026 1:20 AM

Fluoguide A/S ("FluoGuide" or the "Company")(STO:FLUO) today releases its results for the period 1 January 2025 - 31 December 2025. The Q4 report is available as attached document to this press release and on FluoGuide's website. "In 2025, FluoGuide achieved several defining milestones that significantly advanced FG001 toward late-stage clinical development and established a clear regulatory pathway toward U.S. approval. The positive clinical...

Read more